MARKET

OCX

OCX

ONCOCYTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.340
-0.100
-2.25%
Opening 10:00 04/22 EDT
OPEN
4.450
PREV CLOSE
4.440
HIGH
4.530
LOW
4.320
VOLUME
94.42K
TURNOVER
--
52 WEEK HIGH
6.57
52 WEEK LOW
1.150
MARKET CAP
385.89M
P/E (TTM)
-9.4615
1D
5D
1M
3M
1Y
5Y
8-K: OncoCyte Corp
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
IRVINE, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing,...
GlobeNewswire · 3d ago
Press Release: Oncocyte Enters the Rapidly -2-
Dow Jones · 3d ago
Oncocyte Enters The Rapidly Growing Immune Therapy Monitoring Market With The Closing Of The Acquisition Of Chronix Biomedical, Inc. >OCX
Oncocyte Enters The Rapidly Growing Immune Therapy Monitoring Market With The Closing Of The Acquisition Of Chronix Biomedical, Inc. >OCX
Dow Jones · 3d ago
Breast Cancer Predictive Genetic Testing Market Analysis By Business Share, Development Trends, Segmentation, Opportunities and Forecast to 2026
The Express Wire · 6d ago
Needham Assigns a Buy Rating on OncoCyte (OCX)
In a report released today, Michael Matson from Needham assigned a Buy rating to OncoCyte (OCX), with a price target of $8.00. The company's shares closed
SmarterAnalyst · 04/14 20:45
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will h...
GlobeNewswire · 04/14 14:00
Oncocyte’s DetermaIO shows correlation with immunotherapy response in bladder cancer
Presenting new data at AACR 2021 annual meeting, Oncocyte (OCX) says its DetermaIO test designed to predict response to immunotherapy demonstrated test performance in bladder cancer,The latest findings add to the
Seekingalpha · 04/11 01:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCX. Analyze the recent business situations of ONCOCYTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCX stock price target is 7.71 with a high estimate of 11.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 36.05M
% Owned: 40.54%
Shares Outstanding: 88.91M
TypeInstitutionsShares
Increased
28
2.31M
New
14
433.24K
Decreased
8
138.77K
Sold Out
12
1.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.52%
Pharmaceuticals & Medical Research
-0.70%
Key Executives
Chairman/Independent Director
Cavan Redmond
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Operating Officer
Albert Parker
Senior Vice President/Chief Accounting Officer
Tony Kalajian
Senior Vice President/Director of Marketing
Padma Sundar
Chief Scientific Officer
Lyndal Hesterberg
Other
Douglas Ross
Independent Director
Andrew Arno
Independent Director
Melinda Griffith
Independent Director
Andrew Last
No Data
About OCX
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

Webull offers kinds of OncoCyte Corp stock information, including NASDAQ:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCX stock methods without spending real money on the virtual paper trading platform.